Form 4: Castle Biosciences Director Daniel Bradbury Sells Shares Under 10b5-1 Plan

Director Daniel Bradbury of Castle Biosciences sold shares of common stock on September 5, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On September 5, 2024, Daniel Bradbury, a director at Castle Biosciences, sold shares of the company's common stock.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 10, 2024.
• He sold 5,017 shares directly at a weighted-average price of $29.024, with individual trades ranging from $28.800 to $29.415.
• He also sold 1,425 shares each from the Daniel Bradbury Irrevocable Descendant's Trust and the Annette Bradbury Irrevocable Descendant's Trust, where he and his spouse are trustees.
• Following these transactions, Bradbury continues to hold shares directly and indirectly through various entities, including BioBrit, LLC, and The Bradbury Family Trust.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to insider trading. It doesn't inherently convey positive or negative sentiment, as it simply reports transactions. The use of a 10b5-1 plan is generally neutral.

Industry Context

Sales by insiders are a common occurrence and are often viewed in the context of the individual's financial planning. The use of a 10b5-1 plan suggests the sales were pre-planned and not based on current inside information.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates